期刊文献+

II~Ⅲ期乳腺癌CEF方案新辅助化疗临床疗效分析

下载PDF
导出
摘要 目的:观察和探讨CEF(环磷酰胺、表阿霉素、氟尿嘧啶)方案在乳腺癌新辅助化疗应用中的临床疗效。方法:对45例乳腺癌患者,确诊后立即行以CEF方案新辅助化疗,化疗3~4个周期,每周期间隔21天。结果:术前达到临床完全缓解CCR2例,有效35例,其中PR23例、MR12例,有效率82%;化疗过程中,未出现严重的化疗毒性。结论:CEF方案新辅助化疗可为乳腺癌的治疗提供更多的选择机会,值得临床推广和应用。
作者 刘刚
出处 《中国中医药咨讯》 2010年第2期140-140,142,共2页
  • 相关文献

参考文献8

  • 1朱元喜,方志沂,马淑资.乳腺癌新辅助化疗不同方案疗效及安全性比较[J].中国肿瘤临床与康复,2001,8(3):18-20. 被引量:32
  • 2Fisher B, Mamounas EP. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer [ J ]. J Clin Oncol, 1995,13 (3) :537 - 540.
  • 3Swain SW, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality app roach of locally advanced nonmetastatic breast cancer[ J]. Cancer Res, 1987,47 (12) :889 - 894.
  • 4Gregory RK, Powles TJ, Salter J, et al. Prognostic relevance of cerb2 expression following neoadjuvant chemotherapy in patients ina randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy [J]. Breast Cancer Res Treat,2000,59(2) :171 -175.
  • 5邵志敏,沈镇宙.新辅助化疗在可切除乳腺癌中的应用[J].外科理论与实践,2001,6(4):255-257. 被引量:9
  • 6沈镇宙,陆劲松.乳腺癌临床研究新进展[J].中国癌症杂志,2001,11(5):388-392. 被引量:69
  • 7Sapunar F, Smith IE. Neoadjuvant chemotherapy for breast cancer [ J]. Ann Med,2000,32 ( 1 ) :43.
  • 8郝春芳,江泽飞,宋三泰.乳腺癌新辅助化疗若干问题的讨论[J].国外医学(肿瘤学分册),2003,30(2):116-118. 被引量:20

二级参考文献30

  • 1[1]Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy of local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol, 1997, 15: 2483.
  • 2[2]Hortobagyi GN. Drug therapy: treatment of breast can cer. N Engl J Med, 1998, 339: 974.
  • 3[3]Fisher B. The evolution of paradigms for the management of breast cancer: A personal perspective. Cancer Res, 1992, 52: 2371.
  • 4[4]Bonadonna G. Evolving concepts in systemic adjuvant treatment of breast cancer. Cancer Res, 1992, 52: 2127.
  • 5[5]Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusionalchemotherapy for large early breast cancer. J Clin Oncol, 1995, 13: 424.
  • 6[6]Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: Preliminary results of a randomized trials: S6. Eur J Cancer, 1994, 30A: 645.
  • 7[7]Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl CancerInst, 1990, 82: 1539.
  • 8[8]Shao ZM, Li J, Wu J, et al. Primary chemotherapy for operable breast cancer induces apoptosis. Breast Cancer Res Treat, 1999, 1288: 1.
  • 9[9]Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol, 1995, 13: 547.
  • 10Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18 [J]. Cancer, 2002,95(4):681-695.

共引文献121

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部